Indication
Glioblastoma IDH Wildtype
4 clinical trials
6 products
Product
EflornithineClinical trial
An Open-label, Phase 1b Study to Evaluate the Safety and Tolerability of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed GlioblastomaStatus: Recruiting, Estimated PCD: 2024-12-15
Product
TemozolomideClinical trial
Study of Metabolic, Genomic and Proteomic Modifications in Relapsed Glioblastoma. Identification or Prognostic Markers in Patients Undergoing Surgery for Relapsed Glioblastoma.Status: Not yet recruiting, Estimated PCD: 2025-07-01
Product
Relapsed GlioblastomaClinical trial
A Phase I-II Study of Niacin in Patients With Newly Diagnosed Glioblastoma Receiving Concurrent Radiotherapy and Temozolomide Followed by Monthly TemozolomideStatus: Recruiting, Estimated PCD: 2026-01-01
Product
NiacinClinical trial
A Phase 1/2 Open-label Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed GlioblastomaStatus: Recruiting, Estimated PCD: 2028-09-01
Product
Debio 0123Product
TMZ